“Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?”, Prospect. Pharm. Sci., vol. 23, no. 2, pp. 42–49, May 2025, doi: 10.56782/pps.361.